M1231, a Novel Bispecific Anti-MUC1xEGFR ADC

Time: 12:00 pm
day: day 1 track 2 am

Details:

M1231 is a bispecific ADC for the
treatment of solid tumors coexpressing MUC1 and EGFR
• Discuss the advantages of a
bispecific ADC approach
• Review mechanism of action and
preclinical profile of M1231